Incyte Stock Today
| INCY Stock | USD 101.18 2.29 2.21% |
PerformanceMild
| Odds Of DistressLow
|
Incyte is trading at 101.18 as of the 29th of January 2026; that is 2.21% down since the beginning of the trading day. The stock's open price was 103.47. Incyte has only a 6 % chance of going through financial distress over the next few years but had a somewhat mild performance during the last 90 days. The performance scores are derived for the period starting the 31st of October 2025 and ending today, the 29th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of November 1993 | Category Healthcare | Classification Health Care |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. The company has 196.32 M outstanding shares of which 10.8 M shares are currently shorted by private and institutional investors with about 5.07 trading days to cover. More on Incyte
Moving against Incyte Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Incyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | William Meury | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, ARCA Biotechnology, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIncyte utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Incyte's leverage profile, showing how much of Incyte's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incyte (INCY) is traded on NASDAQ Exchange in USA and employs 2,617 people. Incyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 19.86 B. Incyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 196.32 M outstanding shares of which 10.8 M shares are currently shorted by private and institutional investors with about 5.07 trading days to cover.
Incyte currently holds about 2.72 B in cash with 335.34 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.24.
Check Incyte Probability Of Bankruptcy
Ownership AllocationThe majority of Incyte outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Incyte to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Incyte. Please pay attention to any change in the institutional holdings of Incyte as this could imply that something significant has changed or is about to change at the company.
Check Incyte Ownership Details
Incyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.6 M | |
| Robeco Institutional Asset Management Bv | 2025-06-30 | 2.4 M | |
| Ubs Asset Mgmt Americas Inc | 2025-06-30 | 2 M | |
| Charles Schwab Investment Management Inc | 2025-06-30 | 1.7 M | |
| Northern Trust Corp | 2025-06-30 | 1.7 M | |
| Man Group Plc | 2025-06-30 | 1.6 M | |
| Bellevue Group Ag | 2025-06-30 | 1.6 M | |
| Legal & General Group Plc | 2025-06-30 | 1.6 M | |
| Norges Bank | 2025-06-30 | 1.4 M | |
| Baker Bros Advisors Lp | 2025-06-30 | 30.7 M | |
| Vanguard Group Inc | 2025-06-30 | 20.1 M |
Incyte Historical Income Statement
Incyte Stock Against Markets
Incyte Corporate Management
| Mr MD | Head VP | Profile | |
| Sheila JD | General VP | Profile | |
| Alexis Smith | Vice Relations | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Patrick Mayes | Vice Research | Profile | |
| Paula Swain | Executive Resources | Profile |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.